Monday’s edition of Forbes Daily covers simmering conflict in the Middle East, the GOP’s embrace of cannabis, Adam Neumann’s latest venture in Saudi Arabia and more.

Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

President Joe Biden told Indo-Pacific allies on Saturday that he believes China’s increasing military assertiveness is an effort to test the region at a turbulent moment for Beijing. Biden’s comments ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...